Peripheral IV Site Monitoring

Concepts

• peripheral iv site monitoring
• iv infiltrations
• monitoring
• peripheral
• sedated patients
• patients
• innovative products
• enhanced patient benefits
• nhs supply chain
• vesicant medications

Location

Description

This market exercise was for the provision of a solution to advise the detection of IV infiltrations and extravasations early that includes the following: • Monitoring equipment and Consumables NHS Supply Chain have a mandate from the Department of Health and Social Care (DHSC) to drive the availability of innovative products to the NHS. NHS Supply Chain believe the product sourced by this contract (which is not covered by any of its current Framework Agreements) falls within this remit as a “disruptive” innovative product and has been identified to provide enhanced patient benefits specifically; Patient - improving patient safety Prevention of Never Event - which can lead to skin necrosis, Amputation, Nerve Damage for our most vulnerable patients, Neonates, paediatrics, sedated patients, critically ill and patients with cognitive deficits, along with Patients receiving Vesicant medications.

Award Detail

CPV Codes

• None found

Legal Justification

Traditional methods rely on periodic clinician assessments, which can miss early signs of infiltration or extravasation, leading to serious complications such as skin necrosis, nerve damage, or medication dosing errors. The ivWatch Patient Monitoring System provides continuous, non-invasive monitoring using optical sensor technology and proprietary algorithms to detect infiltrations at their earliest stages, often before visible signs are present. iv.Watch technology has demonstrated exceptional clinical value in preventing infiltration and extravasation injuries associated with peripheral intravenous (PIV) therapy. This innovation enhances patient safety, reduces liability, and complements clinician assessments, addressing the limitations of periodic monitoring. Research has been carried out on the benefits of the iv Watch technology and can be found in the British Journal of Nursing: British Journal of Nursing - Addressing and mitigating the high costs of extravasation and infiltration to patients and healthcare organisations Due to the absence of competition for technical reasons and that the Manufacturer is only just entering the UK market, only this supplier/distributor can supply the goods required. Procurement Act 2023, Section 41, Schedule 5, Section 5 (b) “There are no reasonable alternatives to those goods, services or works” n/a

Other Information

NHS Supply Chain intends to enter into a Framework Agreement (FAG) with an identified supplier of these products/services (alongside the existing framework Infusion Pumps Administration) following a 10 calendar day publication of a Transparency notice should there only be only 1 available supplier using procedure Direct Award as defined in the Procurement Act 2023. The Term of this Framework Agreement is anticipated to be 12 months, with the option to extend to a maximum term of 48 months. As part of its strategy, NHS Supply Chain anticipates engaging with suppliers of these products/services with a view to ultimately include this solution within the scope of the Framework for Infusion Pumps Administration Sets and Associated products which is due to renewal on 30th September 2026 The Framework Agreement will be between NHS Supply Chain and the Supplier, however 1) NHSSC, 2) any NHS Trust; 3) any other NHS entity; 4) any government department, agency or other statutory body and/or 5) any private sector entity active in the UK healthcare sector will be able to enter into a direct contract with the Supplier for any of the supplies and/or services under the Framework. Electronic ordering will be used, and electronic invoicing will be accepted, and electronic payment will be used. For the avoidance of doubt and notwithstanding the estimate indicated, NHSSC does not guarantee any level of purchase through the framework and advises applicants that the framework shall be established on a non-exclusive basis. ** PREVIEW NOTICE, please check Find a Tender for full details. **